Is combination chemotherapy of cisplatin and gemcitabine in the first-line treatment of advanced gallbladder cancer the right choice? A study in indian patients from the gangetic belt

2020 ◽  
Vol 9 (3) ◽  
pp. 63
Author(s):  
Rahul Sud ◽  
Kishore Kumar ◽  
Pradeep Jaiswal
Keyword(s):  
Gallbladder Cancer ◽  
Combination Chemotherapy ◽  
Line Treatment ◽  
First Line ◽  
Indian Patients ◽  
The Right ◽  
Advanced Gallbladder Cancer ◽  
First Line Treatment

Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer

2019 ◽  
Vol 30 (3) ◽  
pp. 302-307 ◽  
Author(s):  
Wan-Cai Que ◽  
Yan-Fang Huang ◽  
Xiao-Yan Lin ◽  
Yan-Qin Lan ◽  
Xin-Yan Gao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer

2012 ◽  
Vol 82 (1) ◽  
pp. 37 ◽  
Author(s):  
Cheon Woo Lee ◽  
Moo-In Park ◽  
Seun Ja Park ◽  
Won Moon ◽  
Hyung Hun Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP) Plus L-Asparaginase As a First-Line Therapy Improves Outcomes In Stage III/IV NK/T-Cell Lymphoma, Nasal Type (NTCL)

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4347-4347
Author(s):  
Miso Kim ◽  
Ki Hwan Kim ◽  
Bhumsuk Keam ◽  
Se-Hoon Lee ◽  
Dong-Wan Kim ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Treatment Outcomes ◽  
Combination Chemotherapy ◽  
Performance Status ◽  
Poor Performance ◽  
Stage Iii ◽  
Poor Performance Status ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Abstract Background The prognosis of NTCL patients presenting in stage III/IV is extremely poor and there is no standard chemotherapy. Although L-asparaginase (L-asp) is known to be effective for NTCL, its significance has not been well demonstrated in a relatively homogenous subset. In addition, there were few studies to evaluate treatment outcomes and prognostic factors in stage III/IV NTCL. This study was undertaken to evaluate the efficacy of L-asparaginase-based combination chemotherapy (IMEP plus L-asp) and prognostic factors in stage III/IV NTCL. Methods A total of 70 patients with newly diagnosed NTCL at stage III/IV were enrolled from 3 Korean centers between Jan 2000 and Feb 2013. All patients received IMEP plus L-asp (N=22) regimens or combination chemotherapy without L-asp (N=48) as a first-line treatment. Recurrent cases were excluded. Clinical prognostic factors, treatment outcomes, and prognostic scores were compared between the groups. Independent prognostic factors for survivals were identified using multivariate analyses. Results The median age was 48.5 years (range, 18-73 years) with a male-to-female ratio of 2.2:1. After a median follow-up period of 12.8 months (range, 1.1-186.6 months), median progression-free survival (PFS) and overall survival (OS) were 5.6 months and 12.3 months, respectively. Clinical factors and treatment outcomes were compared between IMEP plus L-asp and chemotherapy without L-asp groups (Table 1). Higher response rate (RR) and complete response (CR) rates were observed in patients treated with IMEP plus L-asp compared with those treated with chemotherapy without L-asp (RR 90.0% vs. 34.8%, P< 0.0001; and CR rates 65.0% vs. 21.7%, P = 0.001). In addition, PFS and OS were significantly higher for IMEP plus L-asp group compared with chemotherapy without L-asp group (Table 1). Use of chemotherapy without L-asp (hazards ratio [HR]=2.29, 95% confidence interval [CI] 1.22-4.29; P = 0.010) and poor performance status (HR=2.10, 95% CI 1.23-3.59; P = 0.007) were independent predictors for reduced PFS. Independent factors adversely affecting OS were poor performance status (HR=1.99, 95% CI 1.08-3.65; P = 0.027), 2 or more extranodal sites (HR=2.91, 95% CI 1.25-6.77; P = 0.013), and chemotherapy without L-asp (HR=3.51, 95% CI 1.53-8.06; P= 0.003). Conclusions L-asparaginase-based combination chemotherapy (IMEP plus L-asp) is active against stage III/IV NTCL and an independent predictor for improved survivals. L-asp containing regimen might be useful as a first-line treatment for stage III/IV NTCL. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document